Management of Lymphatic Malformations

  • Kurosh Parsi


Lymphatic malformations (LMs) are congenital anomalies of the lymphatic system occurring in 1 in 2000–4000 births. These anomalies are present at birth but may not be apparent until later in life. Other congenital vascular malformations include venous malformations (VMs), capillary malformations (CMs) and arteriovenous malformations (AVMs). VMs are the most common vascular malformations followed by LMs and CMs. Fortunately, AVMs are the least common but the most aggressive and the most difficult to treat.



I am grateful to Dr. David Connor for his assistance with the preparation of the manuscript.


  1. 1.
    Perkins JA, Manning SC, Tempero RM, Cunningham MJ, Edmonds Jr JL, Hoffer FA, et al. Lymphatic malformations: review of current treatment. Otolaryngol Head Neck Surg. 2010;142(6):795–803. e1CrossRefPubMedGoogle Scholar
  2. 2.
    Parsi K, Myers KA. Tumours and fistulae. In: Myers KA, Clough AM, editors. Practical vascular ultrasound: an illustrated guide. Boca Raton: CRC Press; 2014. p. 215–28.Google Scholar
  3. 3.
    Sierre S, Teplisky D, Lipsich J. Vascular malformations: an update on imaging and management. Arch Argent Pediatr. 2016;114(2):167–76.PubMedGoogle Scholar
  4. 4.
    Koo HJ, Lee JH, Kim GY, Choi YJ, Baek JH, Choi SH, Nam SY, Kim SY, Suh DC. Ethanol and/or radiofrequency ablation to treat venolymphatic malformations that manifest as a bulging mass in the head and neck. Clin Radiol. 2016;71(10):1070.e1–7.Google Scholar
  5. 5.
    Ha J, Yu YC, Lannigan F. A review of the management of lymphangiomas. Curr Pediatric Rev. 2014;10(3):238–48.CrossRefGoogle Scholar
  6. 6.
    Adams DM, Trenor 3rd CC, Hammill AM, Vinks AA, Patel MN, Chaudry G, et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics. 2016;137(2):e20153257.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Hammill AM, Wentzel M, Gupta A, Nelson S, Lucky A, Elluru R, et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer. 2011;57(6):1018–24.CrossRefPubMedGoogle Scholar
  8. 8.
    Danial C, Tichy AL, Tariq U, Swetman GL, Khuu P, Leung TH, et al. An open-label study to evaluate sildenafil for the treatment of lymphatic malformations. J Am Acad Dermatol. 2014;70(6):1050–7.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Koshy JC, Eisemann BS, Agrawal N, Pimpalwar S, Edmonds JL. Sildenafil for microcystic lymphatic malformations of the head and neck: a prospective study. Int J Pediatr Otorhinolaryngol. 2015;79(7):980–2.CrossRefPubMedGoogle Scholar
  10. 10.
    Rankin H, Zwicker K, Trenor 3rd CC. Caution is recommended prior to sildenafil use in vascular anomalies. Pediatr Blood Cancer. 2015;62(11):2015–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Ozeki M, Kanda K, Kawamoto N, Ohnishi H, Fujino A, Hirayama M, et al. Propranolol as an alternative treatment option for pediatric lymphatic malformation. Tohoku J Exp Med. 2013;229(1):61–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Gilony D, Schwartz M, Shpitzer T, Feinmesser R, Kornreich L, Raveh E. Treatment of lymphatic malformations: a more conservative approach. J Pediatr Surg. 2012;47(10):1837–42.CrossRefPubMedGoogle Scholar
  13. 13.
    Balakrishnan K, Menezes MD, Chen BS, Magit AE, Perkins JA. Primary surgery vs primary sclerotherapy for head and neck lymphatic malformations. JAMA otolaryngol Head Neck Surg. 2014;140(1):41–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Goswamy J, Penney SE, Bruce IA, Rothera MP. Radiofrequency ablation in the treatment of paediatric microcystic lymphatic malformations. J Laryngol Otol. 2013;127(3):279–84.CrossRefPubMedGoogle Scholar
  15. 15.
    Zhou Q, Zheng JW, Mai HM, Luo QF, Fan XD, Su LX, et al. Treatment guidelines of lymphatic malformations of the head and neck. Oral Oncol. 2011;47(12):1105–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Manning SC, Perkins J. Lymphatic malformations. Curr Opin Otolaryngol Head Neck Surg. 2013;21(6):571–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Francis CS, Rommer EA, Kane JT, Iwata K, Panossian A. Limited-incision surgical debulking of lymphatic malformations using ultrasound-assisted liposuction. Plast Reconstr Surg. 2012;130(6):920e-2e.CrossRefGoogle Scholar
  18. 18.
    Tavakkolizadeh A, Wolfe KQ, Kangesu L. Cutaneous lymphatic malformation with secondary fat hypertrophy. Br J Plast Surg. 2001;54(4):367–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Mitsukawa N, Satoh K. New treatment for cystic lymphangiomas of the face and neck: cyst wall rupture and cyst aspiration combined with sclerotherapy. J Craniofac Surg. 2012;23(4):1117–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Harmoush S, Chinnadurai P, El Salek K, Metwalli Z, Herce H, Bhatt A, et al. Multimodality image-guided sclerotherapy of low-flow orbital vascular malformations: report of single-center experience. J Vasc Interv Radiol. 2016;27:987–95.CrossRefPubMedGoogle Scholar
  21. 21.
    Schook CC, Mulliken JB, Fishman SJ, Grant FD, Zurakowski D, Greene AK. Primary lymphedema: clinical features and management in 138 pediatric patients. Plast Reconstr Surg. 2011;127(6):2419–31.CrossRefPubMedGoogle Scholar
  22. 22.
    Connor DE, Cooley-Andrade O, Goh WX, Ma DD, Parsi K. Detergent sclerosants are deactivated and consumed by circulating blood cells. Eur J Vasc Endovasc Surg. 2015;49(4):426–31.CrossRefPubMedGoogle Scholar
  23. 23.
    Parsi K, Exner T, Connor DE, Herbert A, Ma DD, Joseph JE. The lytic effects of detergent sclerosants on erythrocytes, platelets, endothelial cells and microparticles are attenuated by albumin and other plasma components in vitro. Eur J Vasc Endovasc Surg. 2008;36(2):216–23.CrossRefPubMedGoogle Scholar
  24. 24.
    Furukawa H, Sasaki S, Oyama A, Hayashi T, Funayama E, Saito N, et al. Ethanol sclerotherapy with ‘injection and aspiration technique’ for giant lymphatic malformation in adult cases. J Plastic Reconstruct Aesthetic Surg. 2011;64(6):809–11.CrossRefGoogle Scholar
  25. 25.
    Shiels 2nd WE, Kenney BD, Caniano DA, Besner GE. Definitive percutaneous treatment of lymphatic malformations of the trunk and extremities. J Pediatr Surg. 2008;43(1):136–9. ; discussion 40CrossRefPubMedGoogle Scholar
  26. 26.
    Farnoosh S, Don D, Koempel J, Panossian A, Anselmo D, Stanley P. Efficacy of doxycycline and sodium tetradecyl sulfate sclerotherapy in pediatric head and neck lymphatic malformations. Int J Pediatr Otorhinolaryngol. 2015;79(6):883–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Cheng J. Doxycycline sclerotherapy in children with head and neck lymphatic malformations. J Pediatr Surg. 2015;50(12):2143–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Kiratli H, Tarlan B. Total clinical regression of an orbital macrocystic lymphatic malformation following intralesional sodium tetradecyl sulphate injection. J AAPOS. 2015;19(1):78–80.CrossRefPubMedGoogle Scholar
  29. 29.
    Kok K, McCafferty I, Monaghan A, Nishikawa H. Percutaneous sclerotherapy of vascular malformations in children using sodium tetradecyl sulphate: the Birmingham experience. J Plastic Reconstruct Aesthetic Surg. 2012;65(11):1451–60.CrossRefGoogle Scholar
  30. 30.
    Cavezzi A, Parsi K. Complications of foam sclerotherapy. Phlebology. 2012;27(Suppl 1):46–51.CrossRefPubMedGoogle Scholar
  31. 31.
    Parsi K. Interaction of detergent sclerosants with cell membranes. Phlebology. 2015;30(5):306–15.CrossRefPubMedGoogle Scholar
  32. 32.
    Cabrera J, Redondo P. Sclerosing treatment of vascular malformations. An Sist Sanit Navar. 2004;27(Suppl 1):117–26.PubMedGoogle Scholar
  33. 33.
    Blaise S, Charavin-Cocuzza M, Riom H, Brix M, Seinturier C, Diamand JM, et al. Treatment of low-flow vascular malformations by ultrasound-guided sclerotherapy with polidocanol foam: 24 cases and literature review. Eur J Vasc Endovasc Surg. 2011;41(3):412–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Burrows PE, Mason KP. Percutaneous treatment of low flow vascular malformations. J Vasc Interv Radiol. 2004;15(5):431–45.CrossRefPubMedGoogle Scholar
  35. 35.
    Ogita S, Tsuto T, Nakamura K, Deguchi E, Iwai N. OK-432 therapy in 64 patients with lymphangioma. J Pediatr Surg. 1994;29(6):784–5.CrossRefPubMedGoogle Scholar
  36. 36.
    Alomari AI, Karian VE, Lord DJ, Padua HM, Burrows PE. Percutaneous sclerotherapy for lymphatic malformations: a retrospective analysis of patient-evaluated improvement. J Vasc Interv Radiol. 2006;17(10):1639–48.CrossRefPubMedGoogle Scholar
  37. 37.
    Orford J, Barker A, Thonell S, King P, Murphy J. Bleomycin therapy for cystic hygroma. J Pediatr Surg. 1995;30(9):1282–7.CrossRefPubMedGoogle Scholar
  38. 38.
    Jia R, Xu S, Huang X, Song X, Pan H, Zhang L, et al. Pingyangmycin as first-line treatment for low-flow orbital or periorbital venous malformations: evaluation of 33 consecutive patients. JAMA Ophthalmol. 2014;132(8):942–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Spence J, Krings T, KG t B, LB d C, Agid R. Percutaneous sclerotherapy for facial venous malformations: subjective clinical and objective MR imaging follow-up results. AJNR Am J Neuroradiol. 2010;31(5):955–60.CrossRefPubMedGoogle Scholar
  40. 40.
    Lee BB, Baumgartner I, Berlien P, Bianchini G, Burrows P, Gloviczki P, et al. Diagnosis and treatment of venous malformations. Consensus Document of the International Union of Phlebology (IUP): updated 2013. Int Angiol. 2015;34(2):97–149.PubMedGoogle Scholar
  41. 41.
    Horbach SE, Rigter IM, Smitt JH, Reekers JA, Spuls PI, van der Horst CM. Intralesional bleomycin injections for vascular malformations: a systematic review and meta-analysis. Plast Reconstr Surg. 2016;137(1):244–56.CrossRefPubMedGoogle Scholar
  42. 42.
    Karavelioglu A, Temucin CM, Tanyel FC, Ciftci AO, Senocak ME, Karnak I. Sclerotherapy with bleomycin does not adversely affect facial nerve function in children with cervicofacial cystic lymphatic malformation. J Pediatr Surg. 2010;45(8):1627–32.CrossRefPubMedGoogle Scholar
  43. 43.
    Saitta P, Krishnamurthy K, Brown LH. Bleomycin in dermatology: a review of intralesional applications. Dermatol Surg. 2008;34(10):1299–313.PubMedGoogle Scholar
  44. 44.
    Kirby JS, Miller CJ. Intralesional chemotherapy for nonmelanoma skin cancer: a practical review. J Am Acad Dermatol. 2010;63(4):689–702.CrossRefPubMedGoogle Scholar
  45. 45.
    Ogita S, Tsuto T, Nakamura K, Deguchi E, Tokiwa K, Iwai N. OK-432 therapy for lymphangioma in children: why and how does it work? J Pediatr Surg. 1996;31(4):477–80.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  1. 1.Department of DermatologySt. Vincent’s HospitalSydneyAustralia
  2. 2.University of New South WalesSydneyAustralia

Personalised recommendations